Regeneron Pharmaceuticals, Inc.REGNNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +10.65% | +10.33% | -3.70% | +3.62% | +0.90% |
| Gross Profit Growth | +14.49% | +14.92% | -5.41% | +2.56% | +0.10% |
| EBITDA Growth | +31.97% | -14.38% | +25.24% | -6.02% | +17.86% |
| Operating Income Growth | -2.60% | -5.76% | -21.25% | +0.93% | -12.95% |
| Net Income Growth | +33.02% | -20.86% | +12.01% | -2.84% | +8.91% |
| EPS Growth | +30.80% | -21.60% | +13.13% | -0.08% | +13.63% |
| EPS Diluted Growth | +29.81% | -20.90% | +15.95% | +3.22% | +18.02% |
| Weighted Average Shares Growth | +1.69% | +1.22% | -1.02% | -2.78% | -4.14% |
| Weighted Average Shares Diluted Growth | +2.47% | +0.00% | -3.39% | -5.89% | -7.75% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +15.88% | +15.89% | -30.90% | +223.28% | +25.36% |
| Free Cash Flow Growth | +18.04% | +28.29% | -42.73% | +576.17% | +27.96% |
| Receivables Growth | +9.36% | +9.61% | +6.49% | -1.87% | -6.88% |
| Inventory Growth | +17.80% | +19.64% | +17.59% | +11.55% | +7.83% |
| Asset Growth | +16.41% | +14.15% | +9.24% | +5.91% | +7.28% |
| Book Value per Share Growth | +15.79% | +11.65% | +10.00% | +9.17% | +10.13% |
| Debt Growth | +0.05% | +0.06% | +0.06% | +0.06% | +0.06% |
| R&D Expense Growth | +36.89% | +35.72% | +6.71% | +16.98% | +17.35% |
| SG&A Expenses Growth | +11.54% | +12.46% | -8.13% | -16.42% | -7.92% |